

Press release

Elicera Therapeutics announces the next safety update in the phase I/II study with ELC-100

Gothenburg, April 23, 2020 - Elicera Therapeutics, a clinical phase cell and gene therapy company that develops immunooncological treatments focusing on CAR T-cells and oncolytic viruses, announced today that six of 12 planned patients have been treated in the ongoing phase I/II study in the treatment of neuroendocrine tumors. ELC-100 has so far not shown any serious side effects in the two different dose groups that have been treated and therefore the Data Safety Monitoring Board (DSMB) has approved that the next dose group of a total of three patients can also start treatment with ELC-100.

The ongoing phase I / II study in the treatment of neuroendocrine tumors, which is carried out in collaboration with Uppsala University as a sponsor, is carried out in two stages where stage one is a so-called dose escalation study of 12 patients which aims to identify the maximum tolerable dose to be tested in another 12 patients in stage two. Step one includes a total of four planned dose groups, with three patients in each group, and based on the good safety profile that ELC-100 has shown so far, the DSMB decided to approve the start of treatment of the third dose group. Of the six patients who received treatment with ELC-100 so far, a partial response has been reported.

About Elicera Therapeutics

Elicera is a clinical stage cell and gene therapy company active in the field of immuno-oncology. Based on the leading research by Professor Magnus Essand's work at Uppsala University, the Company has four drug candidates, two in the field of CAR-T cells and two in the field of oncolytic viruses. Most advanced is ELC-100, an oncolytic virus for NET which is Phase I/II, while ELC-301, an enhanced CAR-T therapy is due to enter Phase I second half of 2022. Elicera has also completed development of a proprietary technology platform called iTANK (immunoTherapies Activated with NAP for efficient Killing) for optimization of any CAR T-cell therapy under development and generation of a second mode of action through activation of CD8+ T-cells against cancer.

For more information, please visit www.elicera.com

Contacts:

Jamal El-Mosleh, CEO

[Tel: +46703319051](tel:+46703319051)

jamal.elmosleh@elicera.com